Literature DB >> 19644136

Current treatment of AL amyloidosis.

Giovanni Palladini, Giampaolo Merlini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19644136      PMCID： PMC2719026          DOI： 10.3324/haematol.2009.008912

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  41 in total

1.  Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Authors:  Vaishali Sanchorawala; Martha Skinner; Karen Quillen; Kathleen T Finn; Gheorghe Doros; David C Seldin
Journal:  Blood       Date:  2007-08-02       Impact factor: 22.113

2.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Authors:  Giovanni Palladini; Francesca Lavatelli; Paola Russo; Stefano Perlini; Vittorio Perfetti; Tiziana Bosoni; Laura Obici; Arthur R Bradwell; GianVico Melzi D'Eril; Roberto Fogari; Remigio Moratti; Giampaolo Merlini
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

3.  Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.

Authors:  Giovanni Palladini; Paola Russo; Mario Nuvolone; Francesca Lavatelli; Vittorio Perfetti; Laura Obici; Giampaolo Merlini
Journal:  Blood       Date:  2007-07-15       Impact factor: 22.113

4.  Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; Dennis A Gastineau
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

5.  High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.

Authors:  David H Vesole; Waleska S Pérez; Marwan Akasheh; Christian Boudreau; Donna E Reece; Christopher N Bredeson
Journal:  Mayo Clin Proc       Date:  2006-07       Impact factor: 7.616

6.  Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Authors:  Vaishali Sanchorawala; Daniel G Wright; Michael Rosenzweig; Kathleen T Finn; Salli Fennessey; Jerome B Zeldis; Martha Skinner; David C Seldin
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

7.  The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Martha Q Lacy; Steven R Zeldenrust; Suzanne R Hayman; Shaji K Kumar; Susan M Geyer; John A Lust; Jacob B Allred; Thomas E Witzig; S Vincent Rajkumar; Philip R Greipp; Stephen J Russell; Brian Kabat; Morie A Gertz
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

8.  Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

Authors:  Adam D Cohen; Ping Zhou; Joanne Chou; Julie Teruya-Feldstein; Lilian Reich; Hani Hassoun; Beth Levine; Daniel A Filippa; Elyn Riedel; Tarun Kewalramani; Michael D Stubblefield; Martin Fleisher; Stephen Nimer; Raymond L Comenzo
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

9.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

10.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Hugh J B Goodman; Helen J Lachmann; Mark Offer; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113
View more
  12 in total

Review 1.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

2.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

Review 3.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Authors:  Q Ping Dou; Jeffrey A Zonder
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

4.  Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.

Authors:  R F Cornell; X Zhong; C Arce-Lara; E Atallah; L Blust; W R Drobyski; T S Fenske; M C Pasquini; J D Rizzo; W Saber; P N Hari
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

5.  Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils.

Authors:  Fernando L Palhano; Jiyong Lee; Neil P Grimster; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-05-07       Impact factor: 15.419

6.  Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.

Authors:  Pamina Kazman; Marie-Theres Vielberg; María Daniela Pulido Cendales; Lioba Hunziger; Benedikt Weber; Ute Hegenbart; Martin Zacharias; Rolf Köhler; Stefan Schönland; Michael Groll; Johannes Buchner
Journal:  Elife       Date:  2020-03-10       Impact factor: 8.140

7.  Primary systemic amyloidosis as a real diagnostic challenge - case study.

Authors:  Sonia Jerzykowska; Maciej Cymerys; Lidia A Gil; Andrzej Balcerzak; Danuta Pupek-Musialik; Mieczysław A Komarnicki
Journal:  Cent Eur J Immunol       Date:  2014-04-17       Impact factor: 2.085

8.  Primary Amyloidosis Presenting as Common Bile Duct Obstruction With Cholangitis.

Authors:  Jennifer Clough; Rahul Shah
Journal:  ACG Case Rep J       Date:  2015-01-16

9.  Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.

Authors:  Xianghua Huang; Qingwen Wang; Wencui Chen; Caihong Zeng; Zhaohong Chen; Dehua Gong; Haitao Zhang; Zhihong Liu
Journal:  BMC Med       Date:  2014-01-06       Impact factor: 8.775

10.  Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides.

Authors:  Emily B Martin; Angela Williams; Tina Richey; Craig Wooliver; Alan Stuckey; James S Foster; Stephen J Kennel; Jonathan S Wall
Journal:  J Transl Med       Date:  2017-12-11       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.